Chromosomal Abnormalities in Endometrial and Ovarian Carcinomas

Abstract

Development and progression of human malignancies involve multiple genetic changes including chromosomal instabilities such as translocations, deletions, and inversions. Chromosomal abnormalities were observed in 23 cases with ovarian and endometrial cancer by cytogenetic studies using a GTG (G bands by trypsin using Giemsa) banding technique. Specific chromosome bands were frequently involved, and were most frequent on chromosomes 1, 2, 3, 5, 12 and 17. Clonal alterations were observed at the cancer breakpoints, such as 1q21, 1q32, 3p21, 7q22, 11q23 in ovarian and 1p36, 1q32, 2p12, 3p21, 7q22, 9q34, 11p15, 11q23, 12q13, 14q11, 14q32, 16p13, 21q22 in endometrial cases. These findings provide evidence that multiple genetic lesions are associated with the patho genesis of endometrial and ovarian cancer.

Machine Learning Supports Long Noncoding RNAs as Expression Markers for Endometrial Carcinoma

“…us, CHD5, commonly found downregulated in cancer due to deletion of region 1p36, where it is located, may act as a master regulator, controlling the key processes for the suppression of a variety of tumors [65]. Clonal alteration was found at the region 1p36 in endometrial cancer [66], which might explain why CHD5 is downregulated with a logFC of -5.40 in our analysis. Furthermore, in our coexpression network, CHD5 is positively and strongly linked to three lncRNAs of our set: TCF4-AS1, LINC02249, and LINC02475, which may indicate that they possibly play a role on the expression of CHD5.…”